Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Institut du Cancer de Montpellier - Val d'Aurelle
Adaptimmune
Mayo Clinic
Trans Tasman Radiation Oncology Group